Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFITOPE AD02 in Early Alzheimer's Disease
NCT01117818Phase 2Completed
- Sponsor
- AFFiRiS
- Start
- Sep 2010
- Primary completion
- Dec 2013
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Peptides
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of affitope ad02 in Alzheimer's disease (AD) (4 arms), sponsored by AFFiRiS. Primary endpoints: Modified Alzheimer's Disease Assessment Scale-Cognitive Subscale at 18 months and Modified Alzheimer's Disease Cooperative Study-Activities of Daily Living at 18 months. Started Sep 2010; status: completed.
02
Drugs
affitope ad02
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01117818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01117818.